{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:14:43Z","timestamp":1791234883879,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Recurrent ischemic priapism is an enigmatic erectile disorder in need of improved clinical interventions to avert its known, potentially serious complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the use of a long-term, continuous phosphodiesterase type 5 (PDE5) inhibitor therapeutic regimen in controlling recurrent ischemic priapism and its feasibility in a clinical management program for the disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>The main outcome measure was reduction in frequency or duration of priapism episodes. A secondary outcome measure was preservation of erectile ability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated the clinical progress of seven patients (age 22\u201337 years) with sickle cell disease-associated \u201cstuttering\u201d priapism (N = 4) and idiopathic recurrent priapism (N = 3), who were counseled and consented to the \u201coff-label\u201d use of the PDE5 inhibitors sildenafil citrate and tadalafil. The medications were administered according to a specified therapeutic regimen based on scientific evidence that chronic PDE5 inhibitor administration in priapism contexts effectively reconditions PDE5 regulatory function in the penis. The duration of clinical follow-up extended through 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All seven patients were confirmed to have recurrent ischemic priapism without identifiable pharmacologic, traumatic, or neoplastic disease associations based on clinical history, physical examination, laboratory testing, and penile diagnostics. PDE5 inhibitor treatment was successful in alleviating or resolving priapism recurrences in six of the seven patients. Erectile function was unchanged in six patients and improved in one patient at last follow-up compared with baseline status. All the patients reported that PDE5 inhibitor therapy was well tolerated and did not cause any adverse effects limiting their continued use of the medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Because of their efficacy, safety, and tolerability as shown in this case series, PDE5 inhibitors would appear to have a possible role in a rigorously implemented clinical management program to control recurrent priapism. However, completion of a controlled clinical trial is necessary to confirm the utility of this treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2006.00333.x","type":"journal-article","created":{"date-parts":[[2006,10,26]],"date-time":"2006-10-26T06:45:27Z","timestamp":1161845127000},"page":"1077-1084","source":"Crossref","is-referenced-by-count":115,"title":["Feasibility of the Use of Phosphodiesterase Type 5 Inhibitors in a Pharmacologic Prevention Program for Recurrent Priapism"],"prefix":"10.1093","volume":"3","author":[{"given":"Arthur L.","family":"Burnett","sequence":"first","affiliation":[{"name":"Johns Hopkins University\u2013Urology , Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[{"name":"Johns Hopkins University\u2013Urology , Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter C.","family":"Champion","sequence":"additional","affiliation":[{"name":"Johns Hopkins University\u2014Medicine , Baltimore , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Musicki","sequence":"additional","affiliation":[{"name":"Johns Hopkins University\u2013Urology , Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,11,1]]},"reference":[{"key":"2024032600154648100_bib1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.ju.0000087608.07371.ca","article-title":"American Urological Association guideline on the management of priapism","volume":"170","author":"Montague","year":"2003","journal-title":"J Urol"},{"issue":"Suppl. 5","key":"2024032600154648100_bib2","first-page":"S39","article-title":"Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism","volume":"13","author":"Berger","year":"2001","journal-title":"Int J Impot Res"},{"key":"2024032600154648100_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1743-6109.2004.10117.x","article-title":"Priapism","volume":"1","author":"Pryor","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600154648100_bib4","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/archinte.1980.00330220022011","article-title":"Priapism and impotence in homozygous sickle cell disease","volume":"140","author":"Emond","year":"1980","journal-title":"Arch Intern Med"},{"key":"2024032600154648100_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(17)38248-4","article-title":"Priapism associated with the sickle cell hemoglobinopathies: Prevalence, natural history and sequelae","volume":"145","author":"Fowler","year":"1991","journal-title":"J Urol"},{"key":"2024032600154648100_bib6","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1073\/pnas.0407183102","article-title":"Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism","volume":"102","author":"Champion","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024032600154648100_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.urology.2005.11.045","article-title":"Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism","volume":"67","author":"Burnett","year":"2006","journal-title":"Urology"},{"key":"2024032600154648100_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-5347(18)33427-X","article-title":"Long-term phosphodiesterase type 5 inhibitor therapy reduces priapic activity in transgenic sickle cell mice","volume":"175","author":"Bivalacqua","year":"2006","journal-title":"J Urol"},{"key":"2024032600154648100_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0090-4295(96)00027-1","article-title":"Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine","volume":"47","author":"Virag","year":"1996","journal-title":"Urology"},{"key":"2024032600154648100_bib10","doi-asserted-by":"crossref","first-page":"1002.e22","DOI":"10.1016\/j.urology.2004.12.003","article-title":"Intracavernosal etilefrine self-injection therapy for recurrent priapism: One decade of follow-up","volume":"65","author":"Teloken","year":"2005","journal-title":"Urology"},{"key":"2024032600154648100_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-5347(17)35520-9","article-title":"Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism","volume":"150","author":"Levine","year":"1993","journal-title":"J Urol"},{"key":"2024032600154648100_bib12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1743-6109.2005.00106.x","article-title":"Idiopathic stuttering priapism treated successfully with low-dose ethinyl estradiol: A single case report","volume":"2","author":"Shamloul","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600154648100_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1743-6109.2006.00281.x","article-title":"Distal cavernosum\u2013glans shunts for ischemic priapism","volume":"3","author":"Lue","year":"2006","journal-title":"J Sex Med"},{"key":"2024032600154648100_bib14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1210\/endo.140.4.6655","article-title":"Effects of castration and androgen replacement on erectile function in a rabbit model","volume":"104","author":"Traish","year":"1999","journal-title":"Endocrinology"},{"key":"2024032600154648100_bib15","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1210\/en.2003-1699","article-title":"Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa","volume":"145","author":"Morelli","year":"2004","journal-title":"Endocrinology"},{"key":"2024032600154648100_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.ijir.3900802","article-title":"Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters","volume":"14","author":"Lin","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024032600154648100_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/mol.104.010678","article-title":"Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation","volume":"68","author":"Musicki","year":"2005","journal-title":"Mol Pharmacol"},{"key":"2024032600154648100_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0022-5347(17)44746-X","article-title":"Priapism: A refined approach to diagnosis and treatment","volume":"136","author":"Lue","year":"1986","journal-title":"J Urol"},{"key":"2024032600154648100_bib19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0022-5347(17)38445-8","article-title":"Recurrent prolonged erections and priapism as a sequela of priapism: Pathophysiology and management","volume":"145","author":"Levine","year":"1991","journal-title":"J Urol"},{"key":"2024032600154648100_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1742-1241.2002.tb11296.x","article-title":"Pharmacology of phosphodiesterase-5 inhibitors","volume":"56","author":"Corbin","year":"2002","journal-title":"Int J Clin Pract"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515314107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515314107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/3\/6\/1077\/47736729\/jsm_3_6_1077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/3\/6\/1077\/47736729\/jsm_3_6_1077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:10:30Z","timestamp":1711401030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/3\/6\/1077\/6883059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,1]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2006,11,1]]},"published-print":{"date-parts":[[2006,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2006.00333.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.722591855.793541086","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,11]]},"published":{"date-parts":[[2006,11,1]]}}}